Andrew, Sarepta has already designed drugs that combine their PMOs with a cell-penetrating peptide. They call them PPMOs.
If you look at Sarepta’s pipeline, it first lists their PMO drug candidates, followed by their PPMO drug candidates. The lead PPMO candidate is about to complete a Phase 1 trial in DMD amenable to Exon 51 skipping (the indication for which eteplirsen was approved).
Phylogica believes it has better-performing CPPs. Hence last month’s “400% Outperformance” announcement. I think you can be sure that the CPPs used for comparison in those animal studies (RXR4, PepK and Pip6a) would be well known to Sarepta.
PYC Price at posting:
3.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)